Hepatitis B virus (HBV) vaccine and diagnostic escape mutants are a growing concern. The principle target of detection, hepatitis B surface antigen (HBsAg), encoded by S, is completely overlapped by the reverse transcriptase encoding P. With the increased incidence of nucleos(t)ide analogue resistance altering P, the concurrent impact on S must be assessed. HBV DNA from 59 HBsAg-positive plasma samples was sequenced across the polymerase/surface region and the amino acid sequence of HBsAg was inferred. ELISAs were formatted containing individually bound monoclonal antibodies directed against three discrete epitopes on HBsAg. Similar point mutations occurring in different genotypes were shown to influence epitope conformation differently, indicating that the genetic backbone is a major factor in predicting phenotype. C-terminal changes associated with antiviral resistance were found to modulate epitope profiles of HBsAg. Treatment options which may promote drug resistance should be avoided to both protect antiviral treatment and prevent facilitation of vaccine and diagnostic escape mutants.
Hepatitis B Virus (HBV) is a family of viruses classified into eight genotypes (A-H) (Norder et al., 2004) . Its genome is made up of four overlapping genes (P, S, C and X) (Seeger et al., 2007) . P codes for the viral polymerase, whilst S, entirely overlapped by P, codes for the envelope protein hepatitis B surface antigen (HBsAg).
There are a number of models for the structure of HBsAg (Chen et al., 1996; Cooreman et al., 2001; Paulij et al., 1999; Stirk et al., 1992; van Hemert et al., 2008) . The major antigenic region of HBsAg, the a determinant, is thought to be a conformational cluster of epitopes located between amino acid residues 120 and 150. In more recent models (Cooreman et al., 2001) , the a determinant comprises an exposed part of the S domain formed of three loops (a plausible mini-loop 121-124; first loop 124-138; second loop 138-147) held together by cysteine residues which form disulphide bonds.
As S and P overlap, any polymerase mutations selected for by antiviral therapy may lead to a coding change in S and altered antigenicity (Torresi et al., 2002b) . Whilst these changes occur downstream of the major epitopes of the a determinant, they nevertheless modulate antigenicity (Sloan et al., 2008; Torresi et al., 2002a) .
This study investigated the significance of single amino acid substitutions on plasma HBsAg epitope profiles and the importance of the genetic backbone on inferring antigenicity from DNA sequence data. The HBsAg is a conserved and functional protein with little variation within genotypes and only limited variation between genotypes. While genotype-specific motifs are consistent within a genotype (Norder et al., 2004) , codon substitutions are nevertheless observed across S (Table 1) and profiling on solid phases coated individually with monoclonal antibodies (mAbs) provides a method of quantifying relative epitope density. Three mAbs were used for this. The first, P2D3, recognizes a conserved sequence in the first loop, reacts in Western blotting and binds to a discrete epitope s121-129 (Ijaz et al., 2003) . mAbs H3F5 and D2H5 were raised against native HBsAg and reacted equally with all specimens in the Couroucé Paris HBsAg panel (Tedder et al., 1983) ; they are unreactive in Western blotting but react with conserved 'conformational' epitopes and exhibit limited reactivity in cross-inhibition studies. Oligopeptide mapping tentatively indicated reactivity to solid-phase oligopeptides spanning s131-142 (H3F5) and s142-147 (D2H5) (J. Duncan, personal communication and amino acid alignments were made. HBV genotype was assigned by phylogenetic and cluster analysis across the HBsAg region using Lasergene 8 software (DNASTAR). HBsAg subtype was assigned into the four main serological subtypes according to codons 122 and 160. Sample variation was defined by amino acid substitutions across the a determinant compared with the genotype consensus.
Microtitre plates coated individually with mAbs (P2D3 and H3F5) were supplied by Abbott. Additional microtitre plates were coated with 100 ml purified D2H5 antibody (2.5 mg ml
21
) diluted in 0.02 M Tris/HCl, pH 7.6, overnight at room temperature, washed using glycine borate wash buffer (Abbott) and blocked using 300 ml 10 % milk powder suspended in PBS for a minimum of 1 h at 4 u C. Immediately prior to use, the plates were washed with glycine borate wash buffer.
For the detection of HBsAg on the mAb solid phase, 100 ml diluted plasma was added to the microtitre plate well and incubated at 37 u C for 60 min. Horseradish peroxidase conjugate (50 ml; polyclonal anti-HBs from Abbott/Murex GE 34/36 assay) was added and the plates were incubated at 37 u C for 30 min. Plates were then washed with glycine borate wash buffer (Abbott). The substrate (100 ml; TMB, Abbott) was added and incubated at 37 u C for 30 min. Reactions were stopped using 50 ml 1 M H 2 SO 4 and read at 450 nm.
The HBsAg content of all plasma samples was quantified (IU ml 21 ) by dilution in normal human plasma negative for all HBV markers (NHP) using the Abbott/Murex GE34/ 36 assay. For analysis, initial dilutions of 100 IU ml 21 were prepared in NHP and serially diluted at half log 10 intervals to 1 IU ml 21 . Each dilution series was then tested in the three single mAb assays as described above.
ELISA optical densities [ODs; cut off OD of negative control (NHP)] were plotted and the part of the curve below the plateau was used for calculations. The area under the curve (AUC) was calculated by breaking the points into trapezoids and totalling the areas (Sloan et al., 2008) . The individual AUC result for each mAb was then expressed as a percentage of the sum of the AUC for all three mAbs (AUC %). This established a linked proportional to the relationship between the reactivity displayed on each of the three mAbs, allowing reactions to be self-controlling for variation in the sample dilution and ELISA conditions.
To define the profiles, AUC lower limits for each mAb were set at three standard deviations below the mean for each genotype; samples giving AUC % reactions below these limits were considered to fall outside the normal range.
Twenty-six hepatitis B e antigen/HBsAg-positive plasmas of genotypes A-E were examined for genotype-specific epitope representation and the mean and standard deviation was determined for their AUC profiles (Fig. 1) . Consistency of reactivity was seen both within and between genotypes, although within genotype E, reactivity was more variable, resulting in a higher standard deviation for AUC representation. The amino acid consensus sequence of genotype E a determinant carries a distinct motif with a change at sT140S and a non-conservative change at sP127L (Norder et al., 2004) , which lies within and potentially alters the P2D3 epitope (Ijaz et al., 2003) . A single genotype E sample carrying proline at s127 nevertheless fell close to the genotype mean. The other genotypic variations (sS3G, sL49P, sT57I and sA184V) fall well outside the a Variation in epitope expression within the a determinant allowed an investigation of the impact of sequence changes in different genetic backbones on the expression of the three mAb-defined epitopes. These were the linear P2D3 epitope, the 'conformational' first loop H3F5 epitope and the 'conformational' second loop D2H5 epitope as described above.
The P2D3 epitope was lost in only one sample, M10 [genotype (g)D; sT123A, sM133I; Table 2 ]. M9 (gA; sT123A) and M13 (gE; sM133L), which carry similar codon changes to those seen in M10, but individually, reacted normally. The sT123A mutation that occurs within the binding region of P2D3 and changes a hydrophilic amino acid to a hydrophobic one does not explain the epitope loss in M10. Substitution in M10 of the methionine at 133 with isoleucine is insufficient on its own to ablate the linear epitope, as sample M34 (gC) and M35 (gD) also have this change yet retain a normal epitope profile for P2D3. Perhaps the combined effect of the sT123A and sM133I changes lead to the burial of a normally exposed amino acid backbone. Alternatively, the different genotypic backbone observed between genotype D and A may mean that an sT123A mutation will affect genotypes D (M10) but not genotype A (M9). This could be further explored by back-mutation studies.
Reduced binding for D2H5 was commonly seen in samples carrying substitutions (M15, gA; M19, gA; M20, gD; M21, gD; M26, gA; M27, gD; M32, gB; M34, gC; M35, gD; M38, gA; M39, gC; Reduced D2H5 epitope expression ranged from minimal loss (M15, gA; M19, gA; M38, gA) to near complete or complete ablation (M20, gD; M21, gD; M32, gB; M35, gD), whilst substitutions at sD144A and sD144E were associated with near complete loss. Total loss was seen most commonly with sG145R, the well-described immune escape mutant (Carman et al., 1990; Hsu et al., 2004; Protzer-Knolle et al., 1998) . Interestingly, this was not invariant, as sample M31 (gC, sG145R), which also carried sI195T, did not influence the expression of the D2H5 epitope. Whilst sG145R has been reported to cause testing failures in genotype C (Datta et al., 2006; Hou et al., 2001) , the addition of the concurrent sI195T, a distant codon change towards the C terminus, in sample M31 (gC) seems to have acted to preserve the HBsAg antigenicity despite a sG145R substitution. Sloan et al. (2008) Major disruption of the a determinant was only seen rarely. Three samples (M34, gC; M35, gD; M39, gC) demonstrated this. Samples M34 (isolated from a patient with acute jaundice and suspected viral reactivation following failed renal transplantation) and M35 (isolated from a long-term HBV carrier who is on haemodialysis, also following a failed renal transplantation) came from patients who had not been exposed to antiviral therapy and the development of such severe ablation of HBsAg epitopes was presumably the result of the selection pressure when HBV escapes in a partially immunosuppressed host. Sample M39 came from a post orthotopic liver transplant patient who had received hepatitis B immunoglobulin prophylaxis at transplantation, but developed an escape mutant.
A recent study highlighted the functional importance of conserved residues required for HBV and hepatitis D virus entry (Salisse & Sureau, 2009 ). Our study identified naturally occurring mutations at s118 (M1), s120 (M5, M6) and s142 (M20, M21, M35), which appear to impact on a determinant antigenicity of some of these residues. It seems likely that plasma HBsAg in vivo is able to tolerate changes in these residues, in spite of the in vitro data which might suggest otherwise.
The effect of nucleos(t)ide analogue resistance-induced polymerase changes on epitope profile was also investigated. Three of eight samples bearing drug-related P mutations -M1 (gC, sT118TTSTT, sW196L/rtM204I), M5 (gD, sP120T, sW196S/rtM204I) and M6 (gD, sP120S, sW196L/rtM204I) -and expressing such C- (Warner & Locarnini, 2008) yet in M33, the viral load was high (10 7 IU ml 21 ). The presence of plasma HBsAg with a normal epitope profile indicates that HBsAg must have been translated from a wild-type genome, yet mutant HBV DNA was also detected, suggesting in vivo complementation (Ziermann & Ganem, 1996) . This raises the question of whether complementation is more common and if so, are errors made in inferring the translated HBsAg amino acid sequence from circulating HBV DNA when the template may reside in a different site? This suggests that we should consider direct peptide sequencing when investigating antigenicity ex vivo.
On the assumption that the plasma DNA sequence identifies the active template, these data show that single amino acid substitutions alone do not always predict epitope loss and it is not possible to accurately infer changes in antigenicity from DNA sequencing. Inconsistencies, where epitope profiles do not match sequence-based predictions and where additional, often distant, codon changes are identified, indicate that these distant mutations may be capable of modulating the a determinant. The importance of considering the sample's genetic backbone when analysing mutations is also clearly demonstrated. For future work in this field, we would advocate a holistic approach, looking at the whole polymerase/surface gene rather than simply the a determinant, using back mutation in vitro and paying careful attention to the genetic backbones used.
